The role of paliperidone extended release for the treatment of bipolar disorder Full Text
Neuropsychiatric Disease and Treatment, 05/09/2012
Marino J et al. – According to the limited available evidence, paliperidone at higher doses of extended release (ER) 9-12 mg/day may be a safe and efficacious treatment option for acute episodes of mania in Bipolar disorder (BD). A once–daily dose formulation may improve patient adherence to treatment; however, the cost of paliperidone ER, which is higher than that of generically available second–generation antipsychotics, and a lack of alternative dosage forms compared with other agents may limit its usefulness in the treatment of BD.
Methods- A literature search was performed from January 1966 through January 2012 using PreMEDLINE, MEDLINE, EMBASE, IPA, and ClinicalTrials.gov to identify articles in English regarding the pharmacology, clinical efficacy, and safety of paliperidone ER in acute mania or mixed episodes or in the maintenance treatment of BD I.
- There are currently three published studies relating to the use of paliperidone ER for the treatment of BD.
- Two of these evaluated paliperidone ER as monotherapy for acute mania, while the other assessed its role as adjunct with a mood stabilizer.
